Growth Metrics

IGC Pharma (IGC) Cash from Operations (2016 - 2025)

IGC Pharma has reported Cash from Operations over the past 16 years, most recently at 2090000.0 for Q3 2025.

  • Quarterly Cash from Operations fell 109.84% to 2090000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 5544000.0 through Sep 2025, down 14.05% year-over-year, with the annual reading at 4795000.0 for FY2025, 7.77% up from the prior year.
  • Cash from Operations was 2090000.0 for Q3 2025 at IGC Pharma, down from 1407000.0 in the prior quarter.
  • Over five years, Cash from Operations peaked at 526000.0 in Q1 2024 and troughed at 2505000.0 in Q1 2021.
  • The 5-year median for Cash from Operations is 1618000.0 (2023), against an average of 1605526.32.
  • Year-over-year, Cash from Operations skyrocketed 65.33% in 2024 and then crashed 109.84% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 2422000.0 in 2021, then skyrocketed by 31.96% to 1648000.0 in 2022, then increased by 3.7% to 1587000.0 in 2023, then rose by 17.01% to 1317000.0 in 2024, then tumbled by 58.69% to 2090000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Cash from Operations are 2090000.0 (Q3 2025), 1407000.0 (Q2 2025), and 730000.0 (Q1 2025).